Clinics and pathology

Disease
Chronic lymphoproliferation Phenotype / cell stem origin B-cell disease; the existence of rare cases of T-CLL has been debated. Epidemiology Annual incidence 30/10 6 ; represents 70% of lymphoid leukaemias, 1/4 of all leukaemias; median age: 60-80 yrs, 2M/1F. Clinics Diagnosis is often delayed, due to the lack of symptoms (therefore, median survival from the begining of the disease may be much more than med. surv. from diagnosis); enlarged lymph nodes; splenomegaly; blood data: lymphocytosis > 4 X 10 9 /l; hypogammaglobulinemia in 60%. Cytology Typically, proliferation of mature small lymphocytes of normal morphology; lymphocytes with more abundant cytoplasm can be present; prolymphocytes must represent less than 10% of the lymphocytes (otherwise, the diagnosis of 'chronic lymphocytic leukaemia-prolymphocytic leukaemia' should be made); expression of sIg with monotypy (monoclonality); CD19+, CD20+, and CD5+ most often. Treatment None in early stage; chemotherapy afterwards.
Evolution
Unrelated causes and disease-related infections are the 2 major causes of death.
Other: autoimmune hemolytic anaemia and thrombocytopenia; transformation into Richter's disease or into prolymphocytic leukaemia (in 10%). Prognosis According to the staging: A (less than 3 lymph nodes, Hb < 10g/dl, platelets < 100 X 10 9 /l): survival not reduced compared to age matched population; B (3 or more lymph nodes; Hb and platelets maintained): median survival of 5 yrs; C (Hb < 10g/dl and/or platelets < 100 X 10 9 /l): median survival of 2 yrs; according to the karyotype: survival is better in cases with a normal karyotype (median: 15 yrs vs 8 yrs with an abnormal karyotype), worse in the 10% of cases where a complex karyotype is found (median: 6 yrs); specific chromosome anomalies have specific prognoses (see below).
Cytogenetics
Cytogenetics, morphological
Clonal anomaly is found in about 50% of cases; complex karyotypes are found in 10%; unrelated clones demonstrating the existence of cells subpopulations are frequent findings in this disease. +12: is found in 15-20% of cases, depending on the use of interphase cytogenetics methods (FISH) and the cell morphology of the cases under study (trisomy 12 is typically found in atypical lymphocyte morphology and CD5-cases, often with an increased number of prolymphocytes, in advanced stages, and is associated with disease progression); trisomy 12 is an adverse prognostic factor (median survival: 5 yrs); found either as the sole anomaly, as an anomaly accompanied by others, or even as an accompanying (secondary) anomaly; present only in a subset of the malignant cell population; region q13-q22 might be of particular pathogenetic importance; 
Genes involved and Proteins
Note: Genes involved as a primary event are still unknown. P53 has been found mutated in 10-15% of cases; adverse prognostic indicator.
